Showing results (91-100 of 301) with videos related to

Sort By:
Pageof 31
Plos One|September 27, 2014
In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNADavid M Goldenberg, Robert J Rooney, Meiyu Loo, et al.
Fertility and Sterility|December 13, 2002
Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometriumRosalyn D Blumenthal, Alice P Taylor, Lisa Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapyDavid M Goldenberg, Robert M Sharkey, Giovanni Paganelli, et al.
Annals of Surgical Oncology|June 16, 2007
Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control groupTorsten Liersch, Johannes Meller, Michael Bittrich, et al.
Bioconjugate Chemistry|January 26, 2012
New lyophilized kit for rapid radiofluorination of peptidesWilliam J McBride, Christopher A D'Souza, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeysThomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, et al.
Blood|April 18, 2009
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphomaEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Cancer Research|September 30, 2010
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cellsEdmund A Rossi, Diane L Rossi, Rhona Stein, et al.
Cancer Research|April 4, 2002
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell linesChris Waskewich, Rosalyn D Blumenthal, Honglan Li, et al.
Blood|June 17, 2006
Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximabRhona Stein, Zhengxing Qu, Susan Chen, et al.
Pageof 31